Paladin (Tor., PLB, $ 11.49) should surpass the $ 100 million (M $) in revenue in 2009 through the acquisition of exclusive marketing rights in Canada’s Dexedrine, a drug from GlaxoSmithKline.
Menu
Paladin (Tor., PLB, $ 11.49) should surpass the $ 100 million (M $) in revenue in 2009 through the acquisition of exclusive marketing rights in Canada’s Dexedrine, a drug from GlaxoSmithKline.
